NR1H4 and hepatocellular carcinoma: FXR inhibits HCC development through the modulation of several metabolic pathways involving BAs, glucose, and lipids, the suppression of liver inflammation, the promotion of tissue repair after liver injury, the expression of partial tumor suppressor genes, and the inhibition of transcription of multiple oncogenes [87,88].